Member access

4-Traders Homepage  >  Shares  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

News SummaryMost relevantAll newsSector news 

DAIICHI S : Notice on Details of the Share Options

07/12/2011 | 05:20am US/Eastern
For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, Corporate Officer, Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126 on Details of the Share OptionsTOKYO, Japan (July 12, 2011) Daiichi Sankyo Company, Limited has announced that the subscription amount and other details of its No.5 share options were decided today. As previously announced, the Board of Directors had reached a decision on June 27, 2011 to issue the said share remuneration-type stock options (share options) to remunerate Directors (excluding Outside Directors) and Corporate Officers

1. Name of share options

Daiichi Sankyo Company, Limited No. 5 share options

2. Total number of share options

2,328 share options (100 shares per one share option) Breakdown

Six (6) Directors: 1,102 share options

Eighteen (18) Corporate Officers: 1,226 share options

3. Subscription amount for share options

111,200 yen per share option

(1,112 yen per share)


Date of Board of Directors resolution: June 27, 2011

React to this article
12:08a RANBAXY LABORATORIES : Sun to focus on R& D after Ranbaxy buyout
03/25 DAIICHI SANKYO : N.C. to get share of $39 million in doctor kickback case
03/25 DAIICHI SANKYO : Findings from Daiichi Sankyo in the Area of Pharmacology Descri..
03/25 Sun Pharmaceuticals completes buyout of Ranbaxy
03/24 Emcure Pharma to Acquire Seven Drugs from Sun Pharma and Ranbaxy Labs
03/23 RANBAXY LABORATORIES : Sun-ranbaxy gets cci nod for divesting brands
03/21 Govt made to ' pop' ` 1,348- cr tax pill
03/20 DAIICHI SANKYO : Launches Methemoglobinemia Treatment Methylene Blue Injection 5..
03/19 AstraZeneca And Daiichi Sankyo To Jointly Commercialise MOVANTIK; Amicus Prov..
03/19 ASTRAZENECA : Collaboration with daiichi sankyo inc
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes